Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

973 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age.
Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Hori M, et al. Among authors: yamanaka s. Circ J. 2014;78(6):1349-56. doi: 10.1253/circj.cj-13-1324. Epub 2014 Apr 7. Circ J. 2014. PMID: 24705469 Free article. Clinical Trial.
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial.
Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Hori M, et al. Among authors: yamanaka s. J Stroke Cerebrovasc Dis. 2014 Feb;23(2):379-83. doi: 10.1016/j.jstrokecerebrovasdis.2013.07.021. Epub 2013 Aug 15. J Stroke Cerebrovasc Dis. 2014. PMID: 23954611 Clinical Trial.
Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF.
Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Uchiyama S, et al. Among authors: yamanaka s. J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1142-7. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.001. Epub 2013 Nov 1. J Stroke Cerebrovasc Dis. 2014. PMID: 24189454 Clinical Trial.
Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial.
Matsumoto M, Hori M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Matsumoto M, et al. Among authors: yamanaka s. Hypertens Res. 2014 May;37(5):457-62. doi: 10.1038/hr.2014.1. Epub 2014 Jan 30. Hypertens Res. 2014. PMID: 24477179 Clinical Trial.
Predictive factors for bleeding during treatment with rivaroxaban and warfarin in Japanese patients with atrial fibrillation - Subgroup analysis of J-ROCKET AF.
Hori M, Matsumoto M, Tanahashi N, Momomura SI, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Cavaliere M, Iekushi K, Yamanaka S; J-ROCKET AF Study Investigators. Hori M, et al. Among authors: yamanaka s. J Cardiol. 2016 Dec;68(6):523-528. doi: 10.1016/j.jjcc.2015.12.003. Epub 2016 Jan 18. J Cardiol. 2016. PMID: 26796348 Free article.
Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry.
Ogawa S, Ikeda T, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iekushi K, Yamanaka S, Yamada T, Inuyama L; Rivaroxaban PostMarketing Surveillance Registry Investigators. Ogawa S, et al. Among authors: yamanaka s. J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2520-2526. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.006. Epub 2014 Sep 20. J Stroke Cerebrovasc Dis. 2014. PMID: 25245483
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iwashiro S, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S. Ikeda T, et al. Among authors: yamanaka s. J Thromb Thrombolysis. 2019 Nov;48(4):653-660. doi: 10.1007/s11239-019-01934-6. J Thromb Thrombolysis. 2019. PMID: 31432451 Free PMC article. Clinical Trial.
Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
Miyamoto S, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Murakawa Y, Iwashiro S, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S. Miyamoto S, et al. Among authors: yamanaka s. J Stroke Cerebrovasc Dis. 2020 Apr;29(4):104584. doi: 10.1016/j.jstrokecerebrovasdis.2019.104584. Epub 2020 Jan 23. J Stroke Cerebrovasc Dis. 2020. PMID: 31983518 Free article.
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.
Murakawa Y, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Hayashi Y, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S. Murakawa Y, et al. Among authors: yamanaka s. Heart Vessels. 2020 Aug;35(8):1125-1134. doi: 10.1007/s00380-020-01587-z. Epub 2020 Apr 6. Heart Vessels. 2020. PMID: 32253531 Free PMC article.
Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
Minematsu K, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Miyamoto S, Murakawa Y, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S. Minematsu K, et al. Among authors: yamanaka s. Cerebrovasc Dis. 2019;48(1-2):53-60. doi: 10.1159/000502883. Epub 2019 Oct 2. Cerebrovasc Dis. 2019. PMID: 31578012
973 results